Main Line Fertility Fort Washington

CLIA Laboratory Citation Details

4
Total Citations
10
Total Deficiencyies
7
Unique D-Tags
CMS Certification Number 39D0909225
Address 467 Pennsylvania Ave, Suite 202b, Fort Washington, PA, 19034
City Fort Washington
State PA
Zip Code19034
Phone(215) 887-2010

Citation History (4 surveys)

Survey - August 20, 2024

Survey Type: Special

Survey Event ID: IW5C11

Deficiency Tags: D2005 D2107 D2016 D2107 D2005 D2016

Summary:

Summary Statement of Deficiencies D2005 ENROLLMENT CFR(s): 493.801(a)(4) Authorize the proficiency testing program to release to HHS all data required to-- (i) Determine the laboratory's compliance with this subpart; and (ii) Make PT results available to the public as required in section 353(f)(3)(F) of the Public Health Service Act. This STANDARD is not met as evidenced by: Based on review of the laboratory's College of American Pathologists (CAP) proficiency testing (PT) evaluation reports, the laboratory director failed to ensure PT data was released by the PT program (CAP) to the state agency, Pennsylvania Deparment of Health (PA SA) in 2024. Findings include: 1. On the day of the PT desk review survey, 08/20/2024, review of the laboratory's CAP PT evaluation reports revealed the laboratory director failed to ensure PT data was released by CAP to the appropriate state agency (PA SA) in 2024. 2. Further review of the CAP PT evaluation reports revealed the PT results were only copied to CMS in 2024. D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of the CASPER 155 report and graded results from the proficiency testing (PT) organizations, American Association of Bioanalysts Medical Laboratory Evaluation (AAB-MLE) and College of American Pathologists (CAP) , the laboratory failed to successfully participate in PT for the endocrinololgy analyte: Human chorionic gonadotropin (HCG). Refer to D2107. D2107 ENDOCRINOLOGY CFR(s): 493.843(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of the CASPER 155 report and graded results from the proficiency testing (PT) organizations, American Association of Bioanalysts Medical Laboratory Evaluation (AAB-MLE) and College of American Pathologists (CAP), the laboratory failed to successfully participate in PT for the endocrinology analyte: Human chorionic gonadotropin (HCG). The laboratory had unsatisfactory scores for the 1st and 2nd Events in 2024. Findings include: Analyte Year Event Score HCG 2024 1 60%. (CAP) HCG 2024 2 60% (AAB-MLE) -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - December 13, 2023

Survey Type: Standard

Survey Event ID: LPT211

Deficiency Tags: D5473

Summary:

Summary Statement of Deficiencies D5473 CONTROL PROCEDURES CFR(s): 493.1256(e)(2)(g) (e) For reagent, media, and supply checks, the laboratory must do the following: (e) (2) Each day of use (unless otherwise specified in this subpart), test staining materials for intended reactivity to ensure predictable staining characteristics. Control materials for both positive and negative reactivity must be included, as appropriate. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on review of the laboratory's sperm morphology quality control (QC) records and interview with the general supervisor (GS), the laboratory failed to document the intended reactivity of the stain used for sperm morphology examinations each day of patient testing in 2023. Finding Include: 1. On the day of the survey, 12/13/2023 at 12: 07 pm, review of the laboratory's sperm morphology stain QC records revealed the laboratory did not document the Astral stain reactivity for sperm morphology examinations each day of patient testing in 2023. 2. Laboratory's sperm morphology stain procedure stated that stain is checked for reactivity each day of use. 3. The GS confirmed the findings above on 05/08/2023 around 01:00 pm. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - January 31, 2022

Survey Type: Standard

Survey Event ID: KSZY11

Deficiency Tags: D5421

Summary:

Summary Statement of Deficiencies D5421 ESTABLISHMENT AND VERIFICATION OF PERFORMANCE CFR(s): 493.1253(b)(1) Each laboratory that introduces an unmodified, FDA-cleared or approved test system must do the following before reporting patient test results: (1)(i) Demonstrate that it can obtain performance specifications comparable to those established by the manufacturer for the following performance characteristics: (1)(i)(A) Accuracy. (1)(i) (B) Precision. (1)(i)(C) Reportable range of test results for the test system. (1)(ii) Verify that the manufacturer's reference intervals (normal values) are appropriate for the laboratory's patient population. This STANDARD is not met as evidenced by: Based on review of the Beckman Unicel Dxl 600 validation records and interview with the Laboratory Director (LD), the laboratory failed to establish criteria for acceptable performance specifications of precision and accuracy for 9 of 9 endocrinology analytes performed on the Beckman Unicel Dxl 600 from 02/14/2020 to 01/31/2022. Findings Include: 1. On the day of survey, 01/31/2022 at 11:15 a.m, review of the of the Beckman Unicel Dxl 600 validation records revealed, the validation performed on 02/14/2020 did not include performance specifications for precision and accuracy for free thyroxine (free T4), free triiodothyronine (free T3), human chorionic gonadotropin (hCG), Follicle-stimulating hormone (FSH), luteinizing hormone (LH), Prolactin (PRL), Progesteron, Estradiol, thyroid stimulating hormone (TSH). 2. From 12/2020 to 01/2022, 74,571 patients were analyzed on the Beckman Unicel Dxl 600. 3. The LD confirmed the findings above on 01/31/2022 at 12:30 p.m.. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - September 4, 2019

Survey Type: Standard

Survey Event ID: VZIO11

Deficiency Tags: D5439 D5449

Summary:

Summary Statement of Deficiencies D5439 CALIBRATION AND CALIBRATION VERIFICATION CFR(s): 493.1255(b) Unless otherwise specified in this subpart, for each applicable test system the laboratory must do the following: Perform and document calibration verification procedure - (b)(1) Following the manufacturer's calibration verification instructions; (b)(2) Using the criteria verified or established by the laboratory under 493.1253(b)(3) -- (b)(2)(i) Including the number, type, and concentration of the materials, as well as acceptable limits for calibration verification; and (b)(2)(ii) Including at least a minimal (or zero) value, a mid-point value, and a maximum value near the upper limit of the range to verify the laboratory's reportable range of test results for the test system; and (b)(3) At least once every 6 months and whenever any of the following occur: (b)(3)(i) A complete change of reagents for a procedure is introduced, unless the laboratory can demonstrate that changing reagent lot numbers does not affect the range used to report patient test results, and control values are not adversely affected by reagent lot number changes. (b)(3)(ii) There is major preventive maintenance or replacement of critical parts that may influence test performance. (b)(3)(iii) Control materials reflect an unusual trend or shift, or are outside of the laboratory's acceptable limits, and other means of assessing and correcting unacceptable control values fail to identify and correct the problem. (b)(3)(iv) The laboratory's established schedule for verifying the reportable range for patient test results requires more frequent calibration verification. This STANDARD is not met as evidenced by: Based on review of the Siemens Immulite 2000 system analyzer records and interview with the laboratory director (LD), the laboratory failed to perform calibration verification at least once every 6 months on 1 of 1 Siemens Immulite 2000 system analyzer in 2017 and 2018. Findings Include: 1. On the day of survey, 09/04/2019, the laboratory could not provide documentation of calibration verification performed at Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- least once every 6 months on 1 of 1 Siemens Immulite 2000 system analyzer used to analyze endocrinology tests in 2017 and 2018. 2. In 2017, (10/12/2017 to 12/31/2017) 5,065 endocrinology patient tests were performed. 3. In 2018, 23,014 endocrinology patient tests were performed. 4. The LD confirmed the findings above on 09/04/2019 around 10:00 am. D5449 CONTROL PROCEDURES CFR(s): 493.1256(d)(3)(ii)(g) Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- At least once a day patient specimens are assayed or examined perform the following for-- Each qualitative procedure, include a negative and positive control material; (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on review of quality control (QC) records, and interview with laboratory director, the laboratory failed to document QC procedures performed on 122 of 122 post vasectomy semen analysis examinations from 2017 to the date of survey. Findings Include: 1. On the day of survey, 09/04/2019, the laboratory could not provide documentation of QC performed on 122 of 122 post vasectomy semen examinations were performed from 10/12/2017 to 09/04/2019. 2. In 2017, (10/12 /2017 to 12/31/2017) 22 post vasectomy semen examinations were performed. 3. In 2018, 63 post vasectomy semen examinations were performed. 4. In 2019, (01/01 /2019 to 05/29/2019) 37 post vasectomy semen examinations were performed. 5. The LD confirmed the findings above on 09/04/2019 around 10:24 am. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access